Juvenile myelomonocytic leukaemia and Noonan syndrome

Journal of Medical Genetics

Volumn 51, Issue 10, 2014, Pages 689-697

  Strullu, Marion ^a,b   Caye, Aurélie ^a,b   Lachenaud, Julie ^a,b   Cassinat, Bruno ^a,c   Gazal, Steven ^d   Fenneteau, Odile ^b   Pouvreau, Nathalie ^b   Pereira, Sabrina ^b   Baumann, Clarisse ^b   Contet, Audrey ^e   Sirvent, Nicolas ^f   Méchinaud, Françoise ^g   Guellec, Isabelle ^h   Adjaoud, Dalila ⁱ   Paillard, Catherine ^j   Alberti, Corinne ^a,b   Zenker, Martin ^k   Chomienne, Christine ^a,c   Bertrand, Yves ^l   Baruchel, André ^b   Verloes, Alain ^a,b   Cavé, Hélène ^a,b   more..

^a INSERM   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e CHU NANCY BRABOIS   (France)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j HÔPITAL DE HAUTEPIERRE   (France)

^k UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^l Institut d'Hémato Oncologie Pédiatrique IHOP   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTARABINE; ETOPOSIDE; MERCAPTOPURINE; PROTEIN TYROSINE PHOSPHATASE SHP 2; PTPN11 PROTEIN, HUMAN;

ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CHILD; CLINICAL FEATURE; CLONAL VARIATION; CODON; COHORT ANALYSIS; DISEASE COURSE; EXOME; FEMALE; FOLLOW UP; GENE SEQUENCE; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HETEROZYGOSITY LOSS; HIDDEN MARKOV MODEL; HUMAN; HUMAN CELL; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTOSIS; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE DISORDER; NEUROBLASTOMA; NEWBORN; NOONAN SYNDROME; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SPLENOMEGALY; THROMBOCYTOPENIA; COMPLICATION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MUTATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MUTATION; NOONAN SYNDROME; PROSPECTIVE STUDIES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 84911433033     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2014-102611     Document Type: Article

References (38)

1. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013;381:333-42.
2. Hasle H. Malignant diseases in Noonan syndrome and related disorders. Horm Res 2009;72(Suppl 2):8-14.
3. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011;157C:83-9.
4. Bader-Meunier B, Tchernia G, Miélot F, Fontaine JL, Thomas C, Lyonnet S, Lavergne JM, Dommergues JP. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 1997;130:885-9.
5. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol Off J Am Soc Clin Oncol 2011;29:573-82.
6. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, Haas O, Harbott J, Hasle H, Kerndrup G, Locatelli F, Mann G, Stollmann-Gibbels B, van't Veer-Korthof ET, van Wering E, Zimmermann M. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997;89:3534-43.
7. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 2011;152:677-87.
8. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res 2009;33:355-62.
9. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991;77:925-9.
10. Fukuda M, Horibe K, Miyajima Y, Matsumoto K, Nagashima M. Spontaneous remission of juvenile chronic myelomonocytic leukemia in an infant with Noonan syndrome. J Pediatr Hematol Oncol 1997;19:177-9.
11. Choong K, Freedman MH, Chitayat D, Kelly EN, Taylor G, Zipursky A. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 1999;21:523-7.
12. Yoshida R, Miyata M, Nagai T, Yamazaki T, Ogata T. A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia. Am J Med Genet A 2004;128A:63-6.
13. Cheong JLY, Moorkamp MH. Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome. J Pediatr Hematol Oncol 2007;29:262-4.
14. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergsträsser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005;106:2183-5.
15. Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 2008;140:610-24.
16. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol 2010;1:2-26.
17. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2010;126:746-59.
18. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hählen K, Hasle H, Licht JD, Gelb BD. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148-50.
19. Pérez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cavé H. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol 2010;151:460-8.
20. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 2005;280:30984-93.
21. Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, Zampino G, Burgt IV, Palleschi A, Petrucci TC, Sorcini M, Schoch C, Foa R, Emanuel PD, Gelb BD. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 2006;78:279-90.
22. Martinelli S, Torreri P, Tinti M, Stella L, Bocchinfuso G, Flex E, Grottesi A, Ceccarini M, Palleschi A, Cesareni G, Castagnoli L, Petrucci TC, Gelb BD, Tartaglia M. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282 V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum Mol Genet 2008;17:2018-29.
23. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308.
24. Van der Burgt I. Noonan syndrome. Orphanet J Rare Dis 2007;2:4.
25. Keren B, Hadchouel A, Saba S, Sznajer Y, Bonneau D, Leheup B, Boute O, Gaillard D, Lacombe D, Layet V, Marlin S, Mortier G, Toutain A, Beylot C, Baumann C, Verloes A, Cavé H; French Collaborative Noonan Study Group. PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet 2004;41:e117.
26. Cambier N, Menot ML, Schlageter MH, Balitrand N, Leblanc T, Bordigoni P, Rohrlich P, Lamagnère JP, Donadieu J, Herbelin C, Puissant C, Gourand F, Baruchel A, Chomienne C. All trans retinoic acid abrogates spontaneous monocytic growth in juvenile chronic myelomonocytic leukaemia. Hematol J Off J Eur Haematol Assoc EHA 2001;2:97-102.
27. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992;51:1229-39.
28. Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal JT. Methylation of AR locus does not always reflect X chromosome inactivation state. Blood 2012;119:e100-109.
29. Bertelsen B, Tümer Z, Ravn K. Three new loci for determining x chromosome inactivation patterns. J Mol Diagn JMD 2011;13:537-40.
30. Bolduc V, Chagnon P, Provost S, Dubé M-P, Belisle C, Gingras M, Mollica L, Busque L. No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans. J Clin Invest 2008;118:333-41.
31. Giovannini L, Cavé H, Ferrero-Vacher C, Boutte P, Sirvent N. A new PTPN11 mutation in juvenile myelomonocytic leukaemia associated with Noonan syndrome. Acta Paediatr 2005;94:636-7.
32. Tartaglia M, Martinelli S, Iavarone I, Cazzaniga G, Spinelli M, Giarin E, Petrangeli V, Carta C, Masetti R, Aricò M, Locatelli F, Basso G, Sorcini M, Pession A, Biondi A. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br J Haematol 2005;129:333-9.
33. Timeus F, Crescenzio N, Baldassarre G, Doria A, Vallero S, Foglia L, Pagliano S, Rossi C, Silengo MC, Ramenghi U, Fagioli F, Cordero di Montezemolo L, Ferrero GB. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome. Oncol Rep 2013;30:553-9.
34. Side LE, Shannon KM. Myeloid disorders in infants with Noonan syndrome and a resident's « rule » recalled. J Pediatr 1997;130:857-9.
35. Becker K, Hughes H, Howard K, Armstrong M, Roberts D, Lazda EJ, Short JP, Shaw A, Patton MA, Tartaglia M. Early fetal death associated with compound heterozygosity for Noonan syndrome-causative PTPN11 mutations. Am J Med Genet A 2007;143A:1249-52.
36. Ekvall S, Hagenäs L, Allanson J, Annerén G, Bondeson M-L. Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype. Am J Med Genet A 2011;155A:1217-24.
37. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004;103:2325-31.
38. Grossmann KS, Rosário M, Birchmeier C, Birchmeier W. The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res 2010;106:53-89.